Protagonist Therapeutics, Inc.

Protagonist Therapeutics, Inc. is a risky bet given it's low Altman Z-score. Companies with a low Altman Z-score have a higher chance of going bankrupt within the next 2 years. Protagonist Therapeutics, Inc. is a real momentum stock, the stock has been booming recently, and may keep doing so in the near future. Protagonist Therapeutics, Inc. is not a good value stock. Protagonist Therapeutics, Inc. is not very popular among insiders. Protagonist Therapeutics, Inc. is a mediocre stock to choose.

Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the r...

News

Protagonist Therapeutics price target raised by $10 at H.C. Wainwright, here's why

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Given Average Recommendation of "Buy" by Brokerages

Ticker Report Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Get Free Report) has been given a consensus rating of "Buy" by the six research firms that are covering the firm, MarketBeat.com reports. Six analysts...\n more…

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Sold by Great Lakes Advisors LLC

Zolmax Great Lakes Advisors LLC reduced its position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 3.8% in the second quarter, according to the company in its most recent filing with the...\n more…

Great Lakes Advisors LLC Decreases Holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

Ticker Report Great Lakes Advisors LLC reduced its position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 3.8% in the 2nd quarter, according to its most recent filing with the Securities and...\n more…

Protagonist Therapeutics (NASDAQ:PTGX) Coverage Initiated by Analysts at Truist Financial

Ticker Report Truist Financial began coverage on shares of Protagonist Therapeutics (NASDAQ:PTGX - Free Report) in a report published on Monday morning, MarketBeat reports. The firm issued a buy rating and a...\n more…

Truist Financial Initiates Coverage on Protagonist Therapeutics (NASDAQ:PTGX)

Zolmax Truist Financial started coverage on shares of Protagonist Therapeutics (NASDAQ:PTGX - Free Report) in a research note published on Monday morning, Marketbeat reports. The brokerage issued a buy...\n more…